New ICER report suggests drug launch prices are outpacing their worth
The median list price of drugs at launch rose 24% from 2022 to 2025, and the net prices of those drugs rose even higher, according to a new report from the Institute for Clinical and ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Most new drugs are still too costly at launch, ICER says biopharmadive.com
